Vida Clinical Research LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$244,084	45
2024	Research	$146,601	61
2023	Research	$233,384	79
2022	Research	$215,986	80
2021	Research	$90,390	57

Breakdown

Who paid Research payments · program years 2021–2025

Sun Pharmaceutical Industries Inc. $410,884 195 payments
Sumitomo Pharma America, Inc. $345,523 58 payments
AbbVie, Inc. $139,670 59 payments
GlaxoSmithKline, LLC. $34,368 10 payments

Studies the money was for Research payments · program years 2021–2025

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $323,212 136 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $133,679 14 payments
Serene $88,448 18 payments
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain $74,584 34 payments
INSPIRE LTE study $67,880 32 payments
A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $59,913 14 payments
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $40,435 9 payments
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain $34,986 19 payments
A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $34,368 10 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $23,048 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.